Summary of Roivant Sciences FY Conference Call (March 03, 2026) Company Overview - **Company**: Roivant Sciences (NasdaqGS:ROIV) - **Event**: 46th Annual TD Cowen Healthcare Conference Key Points PDUFA Date and Drug Launch - The PDUFA date for Roivant's therapy is set for the third quarter of 2026, with a planned launch by the end of September 2026 [6][8] - The company received a priority review from the FDA, indicating confidence in the therapy's data quality [10] Market Expectations and Physician Feedback - Surveys indicate that physicians expect a 30% market share for the new therapy, which aligns with historical accuracy of such surveys [12][13] - There is significant excitement among physicians regarding the potential to reduce steroid burden for patients [16] Treatment Landscape - Approximately 75% of the 40,000 patients tracked are currently managed with DMARDs and oral steroids, while 25% are on IVIG or off-label treatments [17][18] - The new therapy is expected to attract patients dissatisfied with current treatments, particularly those with high steroid burdens [19][20] Efficacy and Labeling - The therapy is anticipated to have a broad indication for dermatomyositis, aiming to serve a wide patient population [13][14] - The study included a steroid taper, and the company plans to provide extensive information on managing steroid reduction [15] Clinical Trials and Data - The NEPTUNE study showed a 29% relapse rate at the 45 mg dose, significantly better than Humira's 62% [23] - The CLARITY studies are designed to mirror NEPTUNE, with a focus on steroid tapering [24][26] Future Studies and Approvals - The company is preparing for phase 3 studies based on positive phase 2 data, with discussions ongoing with the FDA regarding trial design [48][49] - The goal is to maintain consistency with successful phase 2 data in future studies [49] Mosliciguat and Other Programs - Mosliciguat is being studied for pulmonary hypertension with promising phase 1 data showing significant peripheral vascular resistance reduction [61] - The phase 2b PHOCUS study is expected to read out data in the second half of the year, focusing on PVR and six-minute walk metrics [62][64] IMVT-1402 for Graves' Disease - Data from the FORWARD studies for Graves' disease is expected next year, with a focus on controlling refractory patients [82][83] - The therapy aims to provide a new treatment option for patients who are currently uncontrolled on antithyroid drugs (ATDs) [82][84] Legal Matters - Ongoing litigation with Moderna regarding intellectual property, with the company feeling confident about its position [92][93] Additional Insights - The company is focused on addressing the needs of patients who are currently dissatisfied with existing therapies, particularly in underdeveloped treatment landscapes [20][73] - There is a strong emphasis on the importance of patient comfort and the potential for new therapies to improve quality of life [70][72]

Core Insights - Priovant Therapeutics announced that the FDA has accepted its New Drug Application (NDA) for brepocitinib for treating dermatomyositis and granted it Priority Review status, with a target action date set for Q3 2026 and a potential launch at the end of September 2026 [1][6] Group 1: FDA Review and Study Results - The Priority Review designation was based on the significant unmet medical need in dermatomyositis and positive results from the Phase 3 VALOR study, which was the longest and largest interventional trial in this area [2][6] - The VALOR study enrolled 241 subjects and demonstrated that brepocitinib 30 mg resulted in statistically significant improvements in the myositis Total Improvement Score (TIS) at Week 52 compared to placebo, with benefits observed as early as Week 4 [4][6] - More than two-thirds of patients on brepocitinib 30 mg achieved a TIS40, which is twice the minimum clinically important difference, while over half also maintained a steroid dependency of ≤2.5 mg/day [4][6] Group 2: Patient Impact and Company Commitment - The medical community has expressed excitement over the potential for brepocitinib to be the first targeted therapy approved for dermatomyositis, addressing a long-standing need for innovative treatments [3][4] - The CEO of Priovant emphasized the company's commitment to working closely with the FDA to expedite the availability of brepocitinib for patients [4][8] Group 3: Safety and Broader Development - The safety profile of brepocitinib appears similar to that of approved JAK and TYK2 inhibitors, with serious infections noted in the 30 mg group but manageable with medical intervention [5][7] - Priovant is also developing brepocitinib for other conditions, including non-infectious uveitis and cutaneous sarcoidosis, indicating a broader therapeutic potential for this compound [8]

Group 1 - Roivant Sciences Ltd. (NASDAQ:ROIV) is considered a promising low-cost stock, with multiple firms raising their price targets following positive Phase 2 data for brepocitinib in cutaneous sarcoidosis [1][2][3] - Citi raised its price target for Roivant Sciences to $35 from $26 while maintaining a Buy rating, citing the drug's growth potential and integrating revenue projections into its financial model [1][4] - H.C. Wainwright also increased its price target to $33 from $26, characterizing the Phase 2 data as impressive and adding this indication to its valuation model [2] - Bank of America raised its price target to $26 from $22 with a Neutral rating, noting that the FQ3 2026 results were in line and highlighting the positive Phase 2 topline results of brepocitinib [3]

Market Overview - Richard Bernstein, CEO of Richard Bernstein Advisors, discussed the equity markets on CNBC, noting a significant broadening of the market since late October 2025 [1] - The unexpected strength of the overall economy has contributed to this shift, with nominal GDP exceeding 8% last quarter, a level not seen since 2006, excluding the post-pandemic period [2] Investment Strategy - Bernstein emphasized a macro-focused investment strategy, avoiding individual stock picks, and questioned the rationale behind paying high valuations for well-known tech stocks when similar growth can be found at lower valuations globally [3] Promising Low-Cost Stocks - A list of 11 promising low-cost stocks was compiled, focusing on those priced between $10 and $30 and favored by elite hedge funds [6] - The strategy of imitating top hedge fund stock picks has historically outperformed the market, with a reported return of 427.7% since May 2014 [7] Company Highlights Roivant Sciences Ltd. (NASDAQ:ROIV) - Roivant Sciences is highlighted as a promising low-cost stock, with a price target raised by Citi to $35 from $26 due to positive Phase 2 data for brepocitinib [8][9] - H.C. Wainwright also increased its price target for Roivant to $33, citing impressive Phase 2 data [9] - Bank of America raised its price target to $26 from $22, noting that FQ3 2026 results were in line with expectations [10] News Corporation (NASDAQ:NWSA) - News Corporation is also listed as a promising low-cost stock, with a recent price target adjustment by Citi to $39 from $40 while maintaining a Buy rating [12] - The company reported a 6% revenue increase to $2.4 billion and a 9% expansion in total segment EBITDA to $521 million for FQ2 2026 [13] - Despite a 21% decline in net income from continuing operations, adjusted EPS rose to $0.40, and profitability margins improved to 22.1% [13] - Performance was driven by the Dow Jones and Digital Real Estate segments, while the News Media segment faced challenges [14]

Core Insights - Roivant Sciences Ltd. (NASDAQ:ROIV) is recognized as a promising healthcare stock under $50, with a revised price target of $38 from TD Cowen, maintaining a Buy rating following positive Phase 2 results for brepocitinib in cutaneous sarcoidosis [1][2] Financial Performance - The company reported $4.5 billion in consolidated cash, cash equivalents, restricted cash, and marketable securities as of December 31, 2025, indicating a strong cash runway towards profitability [3] Product Development - Brepocitinib 45 mg showed significant improvement in cutaneous sarcoidosis disease activity, with rapid and sustained efficacy across all measured endpoints and a consistent safety profile [2] - An NDA has been submitted to the FDA for brepocitinib in dermatomyositis, with topline data from Phase 3 studies in non-infectious uveitis expected in the second half of 2026 [2] - The company is actively exploring additional indications for brepocitinib [2] Product Portfolio - Roivant Sciences Ltd. develops transformative medicines, with a product portfolio that includes Vtama, Batoclimab, Brepocitinib, Namilumab, and RVT-2001, targeting various therapeutic areas such as oncology, immunology, dermatology, and hematology [4]

Core Insights - Roivant Sciences Ltd. (NASDAQ:ROIV) experienced a significant share price increase of 19.4% week-on-week, reaching an all-time high due to positive results from its pipeline projects, including a new drug application (NDA) submission [1][3]. Company Performance - On Friday, Roivant's stock peaked at $25.95 before closing at $25.82, reflecting a 22.14% increase for the day [2]. - The company reported a net loss of $265.89 million for the third quarter ending December 31, a stark contrast to a net income of $169 million in the same period the previous year [6]. Clinical Trials and Developments - Roivant's unit, Priovant, reported a 22.3% improvement in the CSAMI-A score for patients with cutaneous sarcoidosis after a 16-week therapy, compared to a 0.7% improvement in the placebo group [3]. - Priovant has submitted an NDA to the FDA for brepocitinib to treat dermatomyositis, with a third clinical trial for non-infectious uveitis expected in the second half of 2026 [4]. - Other business units, Immunovant and Pulmovant, are conducting clinical trials for various difficult-to-treat conditions, including rheumatoid arthritis and pulmonary hypertension [5].

Core Insights - Roivant Sciences is a biopharmaceutical company focused on developing transformative medicines and has gained attention for its innovative drug development approach [1] - The company has seen a significant increase in stock price and market interest, particularly due to promising data from its drug Brepocitinib [2][3] Group 1: Stock Performance - Cowen & Co. maintained a "Buy" rating for Roivant Sciences, with the stock priced at $25.82, reflecting confidence in the company's potential [2] - The stock has increased by 22.14%, or $4.68, indicating strong market interest [2] - Roivant's stock reached a new 52-week high of $25.92, showcasing investor optimism about its future prospects [3] Group 2: Market Capitalization and Trading Activity - Roivant's market capitalization is approximately $17.96 billion, indicating a significant presence in the biotech industry [4][6] - The stock's trading volume is 23.84 million shares, reflecting active investor engagement [4] - The stock fluctuated between $23.97 and $25.95, underscoring its dynamic market performance [4] Group 3: Growth Trajectory - With a 52-week low of $8.73, Roivant's current price of $25.82 highlights its impressive growth trajectory [5] - The advancements with Brepocitinib position Roivant as a potential successor to Telavant, suggesting a promising future in the biopharmaceutical sector [5]

Core Insights - The article provides an analysis of a specific company, focusing on its financial performance and market position, but does not offer exhaustive details or personalized investment advice [2][3] Financial Performance - The company reported a significant increase in revenue, with a year-over-year growth of 15%, reaching $1.5 billion in the last quarter [2] - Operating income also saw a rise, up by 10% to $300 million, indicating improved operational efficiency [2] Market Position - The company has strengthened its market share, now holding 25% of the industry, which reflects a competitive advantage over its peers [2] - Recent strategic partnerships have been established, aimed at expanding the company's reach in emerging markets [2] Future Outlook - Analysts predict continued growth, with expectations of a 12% increase in revenue for the next fiscal year, driven by new product launches and market expansion [2] - The company is investing heavily in research and development, allocating $200 million to innovate and enhance its product offerings [2]

分组1 - Roivant Sciences Ltd. reported a quarterly loss of $0.24 per share, better than the Zacks Consensus Estimate of a loss of $0.27, representing an earnings surprise of +9.43% [1] - The company has surpassed consensus EPS estimates two times over the last four quarters [2] - Montes Archimedes Acquisition posted revenues of $2 million for the quarter ended December 2025, missing the Zacks Consensus Estimate by 67.32%, compared to year-ago revenues of $9.02 million [2] 分组2 - The stock of Montes Archimedes Acquisition has lost about 2.6% since the beginning of the year, while the S&P 500 has declined by 0.7% [3] - The earnings outlook for Montes Archimedes Acquisition is crucial for investors, as it includes current consensus earnings expectations for upcoming quarters [4] - The estimate revisions trend for Montes Archimedes Acquisition was favorable ahead of the earnings release, resulting in a Zacks Rank 2 (Buy) for the stock [6] 分组3 - The current consensus EPS estimate for the coming quarter is -$0.28 on $7.3 million in revenues, and -$1.13 on $19.19 million in revenues for the current fiscal year [7] - The Medical - Biomedical and Genetics industry is currently in the top 37% of the Zacks industries, indicating a favorable outlook for stocks in this sector [8] - TScan Therapeutics, Inc., another company in the same industry, is expected to report a quarterly loss of $0.27 per share, with revenues projected to be $4.08 million, up 509% from the year-ago quarter [9]

Financial Data and Key Metrics Changes - The company reported a non-GAAP net loss of $167 million for the quarter, with R&D expenses at $165 million and G&A expenses at $175 million [30] - The company maintains a strong cash position with $4.5 billion in consolidated cash, providing ample capital to reach profitability [30] Business Line Data and Key Metrics Changes - The NDA for brepocitinib in dermatomyositis has been submitted, and the phase 2b study for 1402 in D2T-RA has fully enrolled [6][7] - The phase 2 study for mosliciguat in PH-ILD has also fully enrolled, with top-line data expected in the second half of the year [7][8] Market Data and Key Metrics Changes - The company is targeting a large addressable patient population for brepocitinib, particularly in orphan inflammatory diseases with high unmet needs [25][36] - The potential market for cutaneous sarcoidosis is estimated to be slightly smaller than dermatomyositis, with around 40,000 eligible patients [79] Company Strategy and Development Direction - The company is focused on expanding the development of brepocitinib into additional indications, emphasizing its potential as a first-in-class therapy for sarcoidosis [35][36] - The company plans to leverage insights from the phase 2 study to inform the design of the phase 3 trial, aiming for a similar size and endpoint duration [79] Management's Comments on Operating Environment and Future Outlook - Management expressed enthusiasm about the strong phase 2 data for brepocitinib, highlighting its potential to address significant patient needs [25][36] - The company anticipates a busy year ahead with multiple pivotal study readouts and potential commercial launches [30][31] Other Important Information - The jury trial against Moderna is scheduled for March 9, with recent favorable decisions regarding summary judgment [29] - The company is exploring further development opportunities for brepocitinib, including other forms of sarcoidosis and related conditions [35][36] Q&A Session Summary Question: What are the further development opportunities for brepocitinib? - Management is enthusiastic about expanding brepocitinib's development, particularly in large orphan markets with high unmet needs [35][36] Question: Can you provide more details on the baseline characteristics of the CSAMI numbers? - There were significant differences in baseline characteristics, including disease duration and morphology, which may have influenced the results [42][43] Question: What is the pricing strategy for brepocitinib? - Pricing has not been finalized, but it is expected to be positioned within the orphan drug pricing envelope [48][50] Question: What are the expectations for the phase 3 trial design? - The phase 3 trial is expected to be similar in size to the phase 2 trial, with final details to be discussed with the FDA [58][79] Question: What percentage of patients in the Beacon study had organ involvement? - Approximately 60% of patients had pulmonary involvement, and exploratory endpoints related to organ involvement were collected but not analyzed yet [83][84]